FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

PRINCETON, N.J.–(BUSINESS WIRE)– April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall

Read more

Pembrolizumab May Be Preferable to Chemo in Certain Patients

NEW YORK (Reuters Health) – Pembrolizumab may have an edge on chemotherapy for microsatellite instability-high (MSI-H) advanced gastric or gastroesophageal-junction

Read more

Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC

A novel radiopharmaceutical was more active than cabazitaxel against metastatic castration-resistant prostate cancer (mCRPC) and caused fewer grade 3/4 adverse

Read more

No Benefit Seen With Everolimus in Early Breast Cancer

Adding everolimus to adjuvant hormone therapy for early ER+, HER2- breast cancer does not offer any benefit over hormone therapy

Read more

Surveillance After Testicular Cancer: Reduced Radiation Exposure

Two new approaches to surveillance imaging after treatment of stage I testicular seminoma sharply reduce or eliminate radiation exposure relative

Read more

Perjeta

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. PERJETA 180903 Contains the active ingredient pertuzumab

Read more